Nucleic acids researchAug 4, 2026

A designed molecule allows precise and adjustable control of CRISPR/Cas12a

CRISPR Gene Editing Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Aug 5, 2026

Abstract

The CasTAC strategy achieves over 1000-fold higher detection sensitivity compared to the conventional one-pot recombinase polymerase amplification-CRISPR/Cas12a assay.

Selective regulation of CRISPR/Cas12a activity can be achieved using a proximity-based approach involving crRNA and phosphorothioate regulators.
The strategy eliminates nonspecific interactions within complex multi-enzyme systems, allowing for more precise control over CRISPR/Cas12a function.
Varying the number of phosphorothioate regulators enables fine-tuning of CRISPR/Cas12a activity to different inhibitory levels.
Improvements in nuclease resistance and single-nucleotide discrimination are associated with the CasTAC strategy.
The approach balances nucleic acid amplification and CRISPR cleavage kinetics, enhancing efficiency in product accumulation.

Simplified

Selective and tunable regulation of clustered regularly interspaced short palindromic repeats (CRISPR)/Cas12a activity enables on-demand control, yet current strategies remain hindered by nonspecific regulation and limited tunability. Inspired by proximity effect, we present a Cas-regulation-targeting chimera (CasTAC) strategy that employs CRISPR RNA (crRNA) as a proximity mediator to carry phosphorothioate regulators to interfere with catalytic or recognition domains of Cas12a and consequently suppress its activity. This crRNA-induced proximity approach can effectively eliminate nonspecific interaction between phosphorothioate regulators and proteins within complex multi-enzyme systems, thereby enabling selective control over CRISPR/Cas12a activity. Furthermore, CRISPR/Cas12a activity can be finely tuned to different inhibitory levels by varying the number of phosphorothioate regulators. The CasTAC strategy also improves nuclease resistance and single-nucleotide discrimination, offering potential advances in the sensitivity of molecular diagnostics and the accuracy of gene editing. Notably, the CasTAC balances the kinetics of nucleic acid amplification and CRISPR cleavage, facilitating efficient product accumulation and resolving compatibility issues in one-pot assays. As a proof of concept, we develop a one-pot, one-step recombinase polymerase amplification-CasTAC assay that achieves over 1000-fold higher detection sensitivity than the conventional one-pot recombinase polymerase amplification-CRISPR/Cas12a assay. The CasTAC strategy provides a versatile framework for fine-tuning Cas activity and advances CRISPR technology toward refined and context-adaptable functionality.

Full Text

Full text is available at the source.

View Full Text ↗

A designed molecule allows precise and adjustable control of CRISPR/Cas12a

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the crispr gene editing brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the crispr gene editing brief